JETREA CARE® can help guide your practice through
every step of the reimbursement process:
1Benefit Verification JETREA CARE® will conduct benefit verification to help
  • Determine if JETREA® is a covered benefit
  • Review medical policy guidelines (if applicable) associated with the patient’s plan requirements
  • Assess where prior authorization (PA) is required and how to obtain PA approval
  • Determine when specialty pharmacy acquisitions are required for JETREA
  • Assist with patient financial considerations

2Prior Authorization Assistance If PA is required by a payer, JETREA CARE® can assist with
  • Obtaining PA forms for JETREA
  • Identifying payer requirements and communicating to physicians’ offices
  • Tracking PA status with the payer

3Coding and
Billing Assistance*
JETREA CARE® provides potential coding and billing guidance including:
  • Diagnosis codes
  • Guidance on wastage documentation, if applicable

4Appeals Support For underpaid or denied claims, JETREA CARE® may provide support with:
  • Identifying reasons for underpayment or denial
  • Clarifying the payer appeals process and related requirements
  • Guidance on appeals submission based on payer requirements
  • Tracking appeal status with the payer
  • Providing guidance on pursuing all levels of appeal, as needed

A patient may qualify for the JETREA CARE® Patient Assistance Program if they are rendered uninsured for the FDA-approved use of JETREA and all appeals have been denied. Qualification for the JETREA CARE® Patient Assistance Program will depend on certain eligibility criteria such as FDA-approved use of JETREA, patient’s gross income not exceeding a predetermined amount, and whether the patient is a resident of the fifty states of the United States, including the District of Columbia and Puerto Rico.

Physicians will be required to complete a patient assistance program (PAP) attestation form.

*Please note that it is the sole responsibility of the provider to select proper coding for rendered products or services and to ensure the accuracy of all claims used in seeking reimbursement.
Enroll your patients in JETREA CARE® to benefit from all our
reimbursement services


JETREA (ocriplasmin) injection, for Intravitreal Injection, 1.25 mg/mL is a proteolytic enzyme indicated for the treatment of
symptomatic vitreomacular adhesion.

Important Safety Information

Warnings and Precautions

  • A decrease of ≥ 3 lines of best-corrected visual acuity (BCVA) was experienced by 5.6% of patients treated with JETREA and 3.2% of patients treated with vehicle in the controlled trials. The majority of these decreases in vision were due to progression of the condition with traction and many required surgical intervention. Patients should be monitored appropriately.
  • Intravitreal injections are associated with intraocular inflammation/infection, intraocular hemorrhage and increased intraocular pressure (IOP). Patients should be monitored and instructed to report any symptoms without delay. In the controlled trials, intraocular inflammation occurred in 7.1% of patients injected with JETREA vs 3.7% of patients injected with vehicle. Most of the post-injection intraocular inflammation events were mild and transient. If the contralateral eye requires treatment with JETREA, it is not recommended within 7 days of the initial injection in order to monitor the post-injection course in the injected eye.
  • Potential for lens subluxation.
  • In the controlled trials, the incidence of retinal detachment was 0.9% in the JETREA group and 1.6% in the vehicle group, while the incidence of retinal tear (without detachment) was 1.1% in the JETREA group and 2.7% in the vehicle group. Most of these events occurred during or after vitrectomy in both groups.
  • Dyschromatopsia (generally described as yellowish vision) was reported in 2% of all patients injected with JETREA. In approximately half of these dyschromatopsia cases there were also electroretinographic (ERG) changes reported (a- and b-wave amplitude decrease).

Adverse Reactions

  • The most commonly reported reactions (≥ 5%) in patients treated with JETREA were vitreous floaters, conjunctival hemorrhage, eye pain, photopsia, blurred vision, macular hole, reduced visual acuity, visual impairment, and retinal edema.

Please see full Prescribing Information for JETREA.

You are encouraged to report side effects of prescription drugs to the FDA. Visit MedWatch or call 1-800-FDA-1088. You may also report side effects of JETREA online directly to ThromboGenics by clicking here if you are a Health Care Professional.

For medical information inquiries, or to report an adverse event or product-related complaint, please call 1-855-253-7396 or email